Consensus estimates for 10x Genomics suggest Q3 2026 revenue of approximately $147.96 million and an EPS loss of $0.29, with the current stock price of $65.70 trading below the $77.50 average analyst target. The central focus for this earnings report is the commercial rollout of the new Atera platform, as investors look for signs that instrument revenue is stabilizing after significant declines in previous quarters.
Analysts are specifically monitoring whether management can navigate manufacturing and supply chain constraints that restricted shipment capacity to roughly 40 units for the second half of 2026. This report is viewed as a pivotal test for the company's ability to defend its spatial biology leadership and validate its full-year 2026 revenue guidance of $610 million to $630 million.